These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37638216)

  • 41. Clostridium difficile infection in the inflammatory bowel disease patient.
    Berg AM; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2013 Jan; 19(1):194-204. PubMed ID: 22508484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease.
    Law CC; Tariq R; Khanna S; Murthy S; McCurdy JD
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1011-1020. PubMed ID: 28206678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic review: Clostridium difficile and inflammatory bowel disease.
    Goodhand JR; Alazawi W; Rampton DS
    Aliment Pharmacol Ther; 2011 Feb; 33(4):428-41. PubMed ID: 21198703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.
    Allegretti JR; Kelly CR; Grinspan A; Mullish BH; Hurtado J; Carrellas M; Marcus J; Marchesi JR; McDonald JAK; Gerardin Y; Silverstein M; Pechlivanis A; Barker GF; Miguens Blanco J; Alexander JL; Gallagher KI; Pettee W; Phelps E; Nemes S; Sagi SV; Bohm M; Kassam Z; Fischer M
    Inflamm Bowel Dis; 2021 Aug; 27(9):1371-1378. PubMed ID: 33155639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis.
    Maharshak N; Barzilay I; Zinger H; Hod K; Dotan I
    Medicine (Baltimore); 2018 Feb; 97(5):e9772. PubMed ID: 29384868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study.
    Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Xie D; Yang YX
    Adv Ther; 2021 May; 38(5):2586-2598. PubMed ID: 33844132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An interleukin-4 polymorphism is associated with susceptibility to Clostridium difficile infection in patients with inflammatory bowel disease: results of a retrospective cohort study.
    Connelly TM; Koltun WA; Sangster W; Berg AS; Hegarty JP; Harris L; Deiling S; Stewart DB
    Surgery; 2014 Oct; 156(4):769-74. PubMed ID: 25239315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.
    Fu N; Wong T
    Curr Infect Dis Rep; 2016 Jun; 18(6):19. PubMed ID: 27137789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting.
    Krishnarao A; de Leon L; Bright R; Moniz H; Law M; Leleiko N; Sands BE; Merrick M; Shapiro J; Wallenstein S; Giacalone J; Shah SA
    Inflamm Bowel Dis; 2015 Mar; 21(3):564-9. PubMed ID: 25581825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
    Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical outcomes for Clostridioides difficile associated diarrhea in inflammatory bowel disease patients versus non-IBD population: A retrospective cohort study.
    Drozdinsky G; Atamna A; Banai H; Ben-Zvi H; Bishara J; Eliakim-Raz N
    Medicine (Baltimore); 2023 Feb; 102(6):e32812. PubMed ID: 36820599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Balram B; Battat R; Al-Khoury A; D'Aoust J; Afif W; Bitton A; Lakatos PL; Bessissow T
    J Crohns Colitis; 2019 Jan; 13(1):27-38. PubMed ID: 30247650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [
    Zhang WT; Zhao HM; Luo YH; Duan JQ; Li CL; You JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Jul; 23(7):718-723. PubMed ID: 34266530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection.
    Bhandari S; Mohammed Abdul MK; Dhakal B; Kreuziger LB; Saeian K; Stein D
    Inflamm Bowel Dis; 2017 Oct; 23(10):1847-1852. PubMed ID: 28837518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study.
    Kokkotis G; Zampeli E; Tzouvala M; Giotis I; Orfanos P; Benetou V; Stoupaki M; Leontidis N; Leonidakis G; Kitsou V; Gaki A; Lagiou P; Michopoulos S; Bamias G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):371-375. PubMed ID: 36827531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases.
    Ananthakrishnan AN; Cagan A; Gainer VS; Cheng SC; Cai T; Szolovits P; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
    Aliment Pharmacol Ther; 2014 May; 39(10):1136-42. PubMed ID: 24641590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.